

MURNIA®
Science that *Soothes*.

Our Mission:

Prevent and Treat Severe Oral Wounds

Years of biotech research went into developing our patented molecular compound for oral mucosa and skin. From daily wellness support to serious wound care, we aim to deliver natural solutions with multi-mechanism protection, comfort, and accelerated healing—**for better outcomes and better lives.**

Our History:

Born from Cancer Wound Care

Murnia’s history began in trying to help cancer patients that experience severe wounds due to toxicity of treatments. Focusing on one of the biggest side effects of cancer therapies, oral mucositis, the Murnia™ team has conducted clinical research with a purpose to prevent severe oral mucositis and radiodermatitis in clinical and observatory trials presented as e-posters at Oral Oncology Congress in 2019 and MASCC - Multinational Association of Supportive Care in Cancer (2022, 2024, 2025).



Oral mucositis wounds affect:


- 98% of all Head and Neck Cancer Patients
- 40% of all Cancer Patients
- 71% of all Transplant Patients

Oral Mucositis Wounds are difficult to treat, cause severe pain, and can lead to malnutrition which:

- Increases the cost of care for patients undergoing these treatments by up to \$70K
- Increases use of addictive opioids
- Treatment interruption, which can affect outcomes

Testing of Patented Murnia™ Molecular Compound Showed:

- ✓ **Mucoadhesive Effect:** Adheres to mucosa with staying effect.
- ✓ **Local Anesthetic Effect:** Analgesic properties of anti-inflammatory sesquiterpenes, rich in Murnia™ compound.
- ✓ **Antimicrobial, antifungal, anti-inflammatory:** Measured effectiveness with bacteria and candida albicans in 3rd party accredited labs.
- ✓ **Reactive Oxygen Species (ROS) Scavenging:** 69% inhibition of free-radicals - antioxidant capacity.
- ✓ **Supports Skin’s Natural Effect:** Helping skin’s natural process of closing wounds.



A History in Oncology - published E Posters:

Study Summary #1



“A Study to Assess Preventative Effect of Murnia™ Mouth Gel of Oral Mucositis on Patients Receiving Radiation Therapy for Head and Neck Cancer.” F. Tokatli*, H. Dagotturen** *Istanbul Aydin Uni. Medical Park Hospital **Umayana, Technopark Istanbul Biocube Research Lab. 2018 /2019

Mucositis: Double Blind Placebo Controlled Clinical Trial (Head and Neck Cancer Patients undergoing Radiation Therapy and Concomitant Therapy)

- ✓ No Grade 3 or 4 Progression in Murnia™ cohort v. placebo.
- ✓ No break in treatment.
- ✓ No opioids. No side effects.

Results presented at:

1. International Academy of Oral Oncology, World Congress – Rome, Italy 2019
2. Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology, Annual Conference – Toronto, Canada 2022



Grade 3

Grade 4

Conclusion: Preliminary results for Murnia™ Gel in prevention and treatment of mucositis for patients receiving RT are promising according to the results from 19 patients. Patient recruitment continues.



Study Summary #2

“Radiodermatitis is one of the most frequently observed acute side effects of radiotherapy. It can have a negative impact on quality of life. The incidence of radiodermatitis with new technology and treatment modalities is not completely understood, but 95% of patients have reported some degree of integumentary system reaction to radiotherapy. This study’s aim was to formulate and investigate the radiodermatitis prevention potential of a cream that contains beeswax, proprietary extract (Murnia™ Molecular Compound), cocoa butter, Hypericum perforatum oil and sweet almond oil instead of petroleum-based ingredients.”

Radio Dermatitis: Large Scale Clinical Observation Study (500 RT Patients receiving RT)

- ✓ Less than 12% progressed to Grade 3 (allergic skin, large breast) a significant reduction vs. current therapies

Results presented at:

1. Integrative Dermatology Symposium, Annual Meeting – Sacramento, USA 2018



Grade 3

Grade 4

Conclusion: The efficacy of various herbal remedies, extracts, tinctures and treatments is well known, and therapeutic herb products are increasingly recognized as desirable alternatives to synthetics. The Revitalizing cream is good for use as a barrier throughout radio-therapy treatments for minimizing risk of radio-dermatitis. It can also be used to relieve symptoms and help with healing if and after dermatitis occurs. The Revitalizing Cream formulated with natural efficacious ingredients instead of petrolatum or mineral oil resolved redness and irritation at a higher rate (95%) for patients undergoing radiotherapy with less adverse effects.